Danaher (DHR) reported its Q2 2025 financial results before market open.
The company posted adjusted earnings of $1.80 per share, surpassing the earnings estimate of $1.64 per share and up from $1.72 per share in the same quarter last year.
Revenue came in at $5.94 billion, exceeding the estimated $5.84 billion and growing from $5.74 billion in Q2 2024.
The company raised its FY 2025 earnings outlook to a range of $7.70 to $7.80, up from the previous guidance of $7.60 to $7.75, aligning with the current earnings estimate of $7.70. Revenue increased by approximately 3.4% compared to estimates and about 3.5% year-over-year.
Adjusted earnings rose roughly 9.8% versus estimates and about 4.7% compared to the prior year.
Earnings Insight
| Date | Time | Symbol | company_name | Period | Metric | Estimate | Actual | Surprise | YrAgo | Growth | sector_industry |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 07/22/2025 | BMO | DHR | Danaher | Q2 2025 | EPS | 1.64 | 1.80 | 9.76 | 1.72 | 4.70 | Healthcare / Diagnostics & Research |
| 04/22/2025 | BMO | DHR | Danaher | Q1 2025 | EPS | 1.64 | 1.88 | 14.63 | 1.92 | -2.10 | Healthcare / Diagnostics & Research |
| 01/29/2025 | BMO | DHR | Danaher Corporation | Q4 2024 | EPS | 1.96 | 2.14 | 9.18 | 2.09 | 2.40 | Healthcare / Diagnostics & Research |
| 10/22/2024 | BMO | DHR | Danaher | Q3 2024 | EPS | 1.57 | 1.71 | 8.92 | 2.02 | -15.30 | Healthcare / Diagnostics & Research |
| 07/23/2024 | BMO | DHR | Danaher | Q2 2024 | EPS | 1.57 | 1.72 | 9.55 | 2.05 | -16.10 | Healthcare / Diagnostics & Research |